1. Academic Validation
  2. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells

  • Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190.
Genc Basha 1 Tatiana I Novobrantseva Nicole Rosin Yuen Yi C Tam Ismail M Hafez Matthew K Wong Tsukasa Sugo Vera M Ruda June Qin Boris Klebanov Marco Ciufolini Akin Akinc Ying K Tam Michael J Hope Pieter R Cullis
Affiliations

Affiliation

  • 1 NanoMedicine Research Group, Department of Biochemistry and Molecular Biology Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada. [email protected]
Abstract

Lipid nanoparticles (LNPs) are currently the most effective in vivo delivery systems for silencing target genes in hepatocytes employing small interfering RNA. Antigen-presenting cells (APCs) are also potential targets for LNP siRNA. We examined the uptake, intracellular trafficking, and gene silencing potency in primary bone marrow macrophages (bmMΦ) and dendritic cells of siRNA formulated in LNPs containing four different ionizable Cationic Lipids namely DLinDAP, DLinDMA, DLinK-DMA, and DLinKC2-DMA. LNPs containing DLinKC2-DMA were the most potent formulations as determined by their ability to inhibit the production of GAPDH target protein. Also, LNPs containing DLinKC2-DMA were the most potent intracellular delivery agents as indicated by confocal studies of endosomal versus cytoplamic siRNA location using fluorescently labeled siRNA. DLinK-DMA and DLinKC2-DMA formulations exhibited improved gene silencing potencies relative to DLinDMA but were less toxic. In vivo results showed that LNP siRNA systems containing DLinKC2-DMA are effective agents for silencing GAPDH in APCs in the spleen and peritoneal cavity following systemic administration. Gene silencing in APCs was RNAi mediated and the use of larger LNPs resulted in substantially reduced hepatocyte silencing, while similar efficacy was maintained in APCs. These results are discussed with regard to the potential of LNP siRNA formulations to treat immunologically mediated diseases.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-112758
    ≥98.0%, Ionizable Cationic Lipid